NanoViricides, Inc (NNVC) http://www.nanoviricides.com/index.html Company Address: 135 Wood St, Suite 200 West Haven, CT 06516 Phone: 203-937-6137 Fax: 203-859-5095 Email: email@example.com CIK:
0001379006 NanoViricides, Inc.
is a development stage company with a unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call "nanoviricides®".
A "nanoviricide" is an antiviral agent designed by the Company to fool a virus into attaching to this agent in the same way that the virus normally attaches to receptors on a cell surface. Once attached, the flexible nanoviricide glob would wrap around the virus and trap it. In the process, the virus could lose its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. Nanoviricides are designed to complete the task of dismantling the virus particle without immune system assistance.
Thus nanoviricides represent the next great advance in "Immunotherapeutics" (antibodies and vaccines,) the well established antiviral strategies. Viruses have developed smart strategies to derail immune system function. This results in failure of antibodies and vaccines.
The nanoviricide technology attempts to circumvent virus escape that results from natural changes in virus structure. Despite all such changes, the cell receptor to which a virus binds remains the same. Nanoviricides mimic this conserved feature of virus binding to its host cell receptor. If a virus "escapes" a properly designed nanoviricide, it would have a reduced ability to attach to the cell receptor and would have become much less pathogenic in the process. Management: http://www.nanoviricides.com/board.html Pipeline: http://www.nanoviricides.com/pipeline.html Recent News: http://finance.yahoo.com/q/h?s=NNVC
Micrographic images of nanoviricide micelles in action against Murine Cytomegalovirus: SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001379006&owner=exclude&count=40 Share Structure: See SEC filings for current share structure Investor Relations:
Amanda Schuon, 310-550-7200 firstname.lastname@example.org All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose. Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement. Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp